1.
Clin Nucl Med
; 41(11): 894-895, 2016 Nov.
Article
in English
| MEDLINE
| ID: mdl-27607162
ABSTRACT
An 81-year-old castrate-resistant prostate cancer man with multiple lymph node, bone, and hepatic metastases received four cycles of Lu-PSMA-617 treatments at our department from May to December 2015. All of his liver metastases showed PSMA expression in Ga-PSMA PET performed before the first cycle. Under this therapy, all of the metastases showed significant regression in size and PSMA expression over time.